Therapeutic Solutions International Announces the Appointment of Michael G. Agadjanyan, Ph.D. to Company Scientific Advisory Board
October 19, 2015 08:55 ET
OCEANSIDE, CA–(Marketwired – Oct 19, 2015) – Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that Michael Agadjanyan, Ph.D. has been appointed to our Scientific Advisory Board.
Dr. Agadjanyan is currently the Vice President, Professor and Head of the Department of Molecular Immunology at the Institute for Molecular Medicine, Huntington Beach, California and Adjunct Professor at the MiND Institute at UCI. He was formally a Visiting Professor at the Wistar Institute and at the University of Pennsylvania, Philadelphia, PA.
Before coming to the US in 1991 he was a Professor at the Mechnikov’s Institute for Vaccines and Sera in Moscow at the Russian Academy of Medicine. He received his professional education in Moscow, earning both a Ph.D. and Doctor of Science (D.Sc.) degree. Dr. Agadjanyan’s training was in the area of molecular immunology, immunochemistry, and vaccine research. In these areas of science he has authored many patents, several book chapters and over one hundred and twenty scholarly articles on vaccines, cellular, and molecular immunologies, being published in top, peer-reviewed journals around the world. His research interests are in the area of the mechanisms of antigen presentation as applied to cancer and infectious disease as well as the development of vaccines and/or immunotherapeutics against cancers, Alzheimer’s disease, and Parkinson’s disease.
In the last 25 years he has received numerous grants from the NIH as well as foundations such as the Susan G. Komen Foundation, and the Alzheimer’s Association supporting studies for the generation of humanized monoclonal antibodies and vaccines.
“We are greatly honored today with the appointment of Dr. Michael Agadjanyan to our Scientific Advisory Board. His background in immunology, immunochemistry, and vaccine research will be immensely valuable to the company as we move some of our projects forward,” said Timothy Dixon, President and CEO of Therapeutic Solutions International.
“I am pleased to join the Scientific Advisory Board of TSOI and I look forward to contributing to the team’s efforts on developing new anti-cancer immunotherapeutics. It is my understanding that the new Scientific Advisory Board of TSOI will not only support current product lines of the company, but also will help to develop a new generation of personalized medicine for cancer patients,” said Dr. Agadjanyan.
About Therapeutic Solutions International, Inc.
The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
- Therapeutic Solutions International, Inc.